Clinical Trial: Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma

U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT06870994) titled 'Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma' on Feb. 21.

Brief Summary: This device phase I/II, first in human, early feasibility study (EFS), open-label, single-arm trial aims to evaluate the safety, tolerability, and preliminary efficacy of Gold Nanorod (GNR)-enabled sub-ablative targeted hyperthermia therapy (THT) in patients with unresectable stage 3C/3D/4M1 cutaneous metastatic malignant melanoma that have failed to respond to systemic checkpoint and localized intra-tumoral immunotherapy. The study will involve up to 10 participants with stable or progressive cutaneous and/or subcutaneous...